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Summary
In October 2019, the U.S. Food and Drug Administration (FDA) allowed marketing of the OraQuick® Ebola Rapid Antigen
Test, a rapid diagnostic test (RDT) for detecting Ebola virus in both symptomatic patients and recently deceased people.
This is the first Ebola RDT that FDA has allowed for marketing in the United States. The RDT should be used only in cases
where more sensitive molecular testing is not available. All OraQuick® Ebola Rapid Antigen Test results are presumptive;
all test results (positive and negative) must be verified through real-time reverse transcriptase polymerase chain reaction
(rRT-PCR) testing at a Laboratory Response Network (LRN) laboratory located in 49 states and at the Centers for Disease
Control and Prevention (CDC). Interpretation of RDT results should be done with caution and in consultation with relevant
public health authorities to ensure appropriate testing and interpretation of results. RDT results should not be used to
rule out Ebola infection or to determine the use or type of infection prevention and control precautions when managing a
patient with Ebola compatible symptoms and epidemiologic risk factors. Healthcare providers with a patient with possible
Ebola virus infection should first contact their local or state public health authorities before any testing is performed. CDC
is available to provide consultation, technical assistance, and confirmatory testing as necessary.
Background
Ebola virus disease (Ebola) is a rare and deadly disease caused by infection with viruses within the genus Ebolavirus.
There are four known species within genus Ebolavirus that are known to cause disease in humans: Ebola virus
(species Zaire ebolavirus), Sudan virus (species Sudan ebolavirus), Bundibugyo virus (species Bundibugyo ebolavirus), and
Taï Forest virus (species Taï Forest ebolavirus). People can become infected through contact with blood or body fluids of a
person infected with or who has died of Ebola. Ebola virus can also be spread through contact with contaminated objects
or infected animals. Symptoms of Ebola can include fever, headache, muscle and joint pain, abdominal pain, weakness
and fatigue, gastrointestinal symptoms including diarrhea and vomiting, and bleeding or bruising.
An outbreak of Ebola (associated with Zaire ebolavirus) is occurring in the South Kivu, North Kivu, and Ituri provinces in
northeastern Democratic Republic of the Congo (DRC). First declared on August 1, 2018, the outbreak is the second
largest Ebola outbreak in history and the largest that has ever occurred in DRC. As of December 9, 2019, more than 3,200
confirmed cases and more than 2,000 confirmed deaths have been reported. Despite this, the risk of Ebola virus infection
for most U.S.-based travelers to DRC is low, and the risk of global spread of Ebola to the United States and elsewhere is
also low. Only those going to the outbreak area or who otherwise have contact with an Ebola-infected person (living or
deceased) are at risk. Family and friends caring for people with Ebola and health care workers who do not use correct
infection control precautions are at higher risk (1).
The OraQuick® Ebola Rapid Antigen Test was originally developed as a tool for rapid presumptive diagnosis of Ebola in
outbreak settings and is useful in low-resource areas where access to more sensitive molecular testing is difficult. This
test is not intended to be used for general Ebola infection screening or testing of asymptomatic people or those without
risk factors and compatible symptoms of Ebola. The test has shown to be capable of detecting antigens for three species
of Ebolavirus: Zaire ebolavirus, Bundibugyo ebolavirus, and Sudan ebolavirus (2).; however, the test cannot differentiate
between species. In the United States, presumptive testing for Ebola virus (Zaire ebolavirus) is available at 69 Laboratory
Response Network (LRN) laboratories located in 49 states using rRT-PCR, accessible through coordination with state or
local public health authorities. Molecular testing at CDC is available to confirm these results and is also required to
differentiate between species of Ebolavirus.
Recommendations
CDC recommends that Ebola virus testing be conducted only for people who have an epidemiologic risk factor within 21
days of symptom onset and who have an Ebola compatible clinical syndrome. The signs and symptoms of Ebola are non-
specific, both in the early and advanced clinical course. Because most travelers are at low to no risk of becoming infected
with Ebola, other more common differentials with similar clinical symptomatology such as malaria, dengue, influenza, or
typhoid should be considered. Since August 1, 2018, CDC has received clinical inquiries from state and local health
departments for 49 ill returning travelers from DRC or the surrounding countries. Of these, testing for Ebola virus was
recommended for one returning traveler. The traveler tested negative for Ebola and was subsequently diagnosed with
malaria.
Healthcare providers interested in testing for Ebola virus in ill returning travelers should isolate the patient and contact
their state or local public health authorities. An assessment of epidemiologic risk factors for Ebola and clinical
presentation and history should be made as quickly as possible to ensure patient care is not compromised. CDC is
available to provide consultation, technical assistance, and confirmatory testing as necessary.
State public health authorities or healthcare facilities in the United States considering integrating the OraQuick® Ebola
Rapid Antigen Test into their Ebola testing algorithms or preparedness protocols should consider the following:
1. The RDT should be used only in circumstances where more sensitive molecular testing is not available.
2. RDTs should be used only in collaboration and consultation with relevant public health authorities to ensure
appropriate testing and interpretation of results.
3. All results (positive and negative) from the OraQuick® Ebola Rapid Antigen Test are presumptive and must be
verified through rRT-PCR testing that is available at 69 LRN laboratories located in 49 states and at CDC. Testing at
LRN laboratories is coordinated through state or local public health authorities.
4. Per existing protocols, specimens that test positive by the Ebola virus rRT-PCR assay at an LRN laboratory must be
forwarded to CDC for confirmatory testing.
5. Negative RDT results alone should not be used to rule out Ebola virus infection or to determine the use or type of
infection prevention and control precautions when managing a patient with compatible symptoms and
epidemiologic risk factors.
6. The OraQuick® Ebola Rapid Antigen Test may result in false positive results in patients that have elevated
rheumatoid factor levels (2). Additionally, potential cross-reactivity of the test with Ebola vaccines or therapeutics is
possible and has not been evaluated, and patients who have received vaccines or therapeutics against Ebola virus
may have false positive or other confounding results (2). It is important to consult with public health authorities prior
to the use of RDTs and to aid in the interpretation of RDT results.
7. Facilities that collect and handle specimens from patients with suspected cases of Ebola should ensure adequate
biosafety protocols are in place for the handling and disposal of all potentially infectious materials to avoid risk of
inadvertent exposure (3). For healthcare providers collecting specimens, appropriate personal protective equipment
should be used (4,5).
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OraSure product information
https://www.orasure.com/products-infectious/products-infectious-OraQuick®-ebola.asp
FDA press release
https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-rapid-diagnostic-test-detecting-ebola-
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CDC Ebola information
https://www.cdc.gov/vhf/ebola/index.html
CDC Traveler’s Health: Ebola in Democratic Republic of the Congo
https://wwwnc.cdc.gov/travel/notices/alert/ebola-democratic-republic-of-the-congo
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https://www.cdc.gov/vhf/ebola/clinicians/evaluating-patients/case-definition.html
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https://www.cdc.gov/vhf/abroad/assessing-vhf-returning-traveler.html
The Laboratory Response Network Partners in Preparedness
https://emergency.cdc.gov/lrn/
WHO Ebola information
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CDC-INFO
https://www.cdc.gov/cdc-info/index.html or 1-800-232-4636
CDC Emergency Operations Center (24 Hour EOC)
770-488-7100
The Centers for Disease Control and Prevention (CDC) protects people’s health and safety by preventing and
controlling diseases and injuries; enhances health decisions by providing credible information on critical health
issues; and promotes healthy living through strong partnerships with local, national and international organizations.
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HAN Message Types
Health Alert: Conveys the highest level of importance; warrants immediate action or attention.
Health Advisory: Provides important information for a specific incident or situation; may not require immediate
action.
Health Update: Provides updated information regarding an incident or situation; unlikely to require immediate
action.
Info Service: Provides general information that is not necessarily considered to be of an emergent nature.
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